SEP 23, 2021 5:00 AM PDT

Enhanced Hamster Cells as Super Drug Factories

WRITTEN BY: Tara Fernandes

Antibodies are highly specialized proteins produced by the immune system that stick on to foreign invaders in the body with exquisite specificity, marking them for destruction. Drug developers have harnessed these powerful molecules for their therapeutic effects—because they’re so specific, they have fewer side effects than other drug formats.

In recent years, antibodies have risen to become the top-selling drugs in the pharmaceutical market, used to treat patients with everything from cancer to autoimmune conditions. The downside, however, is that the process of manufacturing antibody drugs is extremely expensive.

Pharmaceutical manufacturers mass-produce these biologics using large cell culture vats containing Chinese hamster ovary (CHO) cells. These genetically engineered hamster cells divide quickly and flourish in these carefully controlled laboratory conditions, churning out antibody proteins that are subsequently purified as treatments. Keeping CHO cell factories going is costly due to the specially-formulated cell culture media they require.

Now, a research and industry collaboration has identified a way of turbocharging CHO cells to ramp up their antibody production, slashing drug production costs. Scientists at the Bioprocessing Technology Institute screened a library of nearly 3,000 small interfering RNAs (or siRNAs), short sequences of RNA that can regulate the expression of genes in cells. They discovered four gene targets that influenced antibody production levels in CHO cells, one of which was Cyp1a2.

Using CRISPR-Cas9 technology, the scientists then snipped out these genes and observed exciting changes in the resulting engineered CHO cells: they produced about 1.7 times more antibodies than the unaltered cells. The researchers hypothesize that future work to screen more siRNA libraries will reveal even more potential drug targets that could further boost biotherapeutic manufacturing outputs.
 

About the Author
PhD
Interested in health technology and innovation.
You May Also Like
FEB 05, 2022
Health & Medicine
What Is Stealth Omicron and What Might It Mean for the Pandemic?
FEB 05, 2022
What Is Stealth Omicron and What Might It Mean for the Pandemic?
Stealth Omicron, also known as the BA.2 subvariant, is considered sibling to Omicron's BA.1 variant that swept ...
MAR 26, 2022
Clinical & Molecular DX
Classifying Biomarkers for Neuropsychiatric Lupus
MAR 26, 2022
Classifying Biomarkers for Neuropsychiatric Lupus
Lupus is an autoimmune disease characterized by one’s immune system targeting and harming itself, and it can impac ...
APR 20, 2022
Immunology
Rare Soil Microbe Shows Promise as New Antibiotic
APR 20, 2022
Rare Soil Microbe Shows Promise as New Antibiotic
  Antibiotic resistance has increased the demand for new antibiotic treatments. Now, researchers have found that a ...
APR 28, 2022
Drug Discovery & Development
Keto Molecule Shows Promise for Treating Colorectal Cancer
APR 28, 2022
Keto Molecule Shows Promise for Treating Colorectal Cancer
A molecule produced when on low-carbohydrate ketogenic diets suppresses the growth of colorectal tumors in the lab. The ...
MAY 15, 2022
Immunology
Long-Term Antibiotics Raise the Risk of Death From a Systemic Fungal Infection
MAY 15, 2022
Long-Term Antibiotics Raise the Risk of Death From a Systemic Fungal Infection
Infections are common, and many are becoming increasingly hard for clinicians to treat. Antibiotics are often used to tr ...
MAY 20, 2022
Health & Medicine
What to Know About the Recent Monkeypox Outbreak
MAY 20, 2022
What to Know About the Recent Monkeypox Outbreak
First COVID, then mysterious hepatitis cases among children, now monkeypox – a rare viral illness being detected i ...
Loading Comments...